


Understanding the cause of joint and tendon dysfunction in osteogenesis imperfecta

June 14 2021



Credit: Pixabay/CC0 Public Domain

Osteogenesis imperfecta (OI) is the most common genetic form of brittle bone disease and results in defects of both bone and connective tissue. OI patients can have significant problems with mobility due to

joint dysfunction due in part to tendinopathy. In a new study published in the journal *Proceedings of the National Academy of Sciences*, researchers at Baylor College of Medicine identify a protein signaling mechanism driving this dysfunction and find that inhibiting this signaling pathway can prevent onset of tendinopathy problems in mouse models.

The researchers studied mouse models of OI in which the *Fkpb10* gene was deleted in tendons and ligaments. The mice developed contracture, a condition in which the tendons harden, leading to joint rigidity and limited motion. As a result of the *Fkpb10* gene deletion, researchers also observed inflammation in the joints and localized formation of cartilage pieces in the tendon, both symptoms of chronic tendinopathy. These symptoms coincided with the increased expression of a gene that impacts cell differentiation.

"We discovered an important signaling protein called Hedgehog, which is key in controlling the formation on cartilage, had been activated in the joints," said Dr. Brendan Lee, corresponding author of the study and Robert and Janice McNair Endowed Chair in Molecular and Human Genetics and professor and chair of the Department of Molecular and Human Genetics at Baylor.

The team, led by Lee and first author and postdoctoral associate in the Lee Lab, Dr. Joohyun Lim, wanted to see if genetic and drug inhibition of the Hedgehog signaling pathway could prevent the onset of symptoms of tendinopathy.

"By giving an FDA-approved Hedgehog signaling inhibitor, we delayed contracture and tendon degeneration and normalized joint function," said Lee, director of the Center for Skeletal Medicine and Biology at Baylor and co-director of the Rolanette and Berdon Lawrence Bone Disease Program of Texas. "We believe this could be a model for treating

tendinopathy, not only in OI patients, but perhaps also in the [general population](#)."

In the future, the researchers will also work to determine if targeting inflammatory pathways as well as Hedgehog signaling can further prevent [tendinopathy](#).

More information: Joohyun Lim et al., "Localized chondro-ossification underlies joint dysfunction and motor deficits in the Fkbp10 mouse model of osteogenesis imperfecta," *PNAS* (2021).
www.pnas.org/cgi/doi/10.1073/pnas.2100690118

Provided by Baylor College of Medicine

Citation: Understanding the cause of joint and tendon dysfunction in osteogenesis imperfecta (2021, June 14) retrieved 20 December 2022 from
<https://medicalxpress.com/news/2021-06-joint-tendon-dysfunction-osteogenesis-imperfecta.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.